Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
NCT04116918 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2019-10-07
Summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.
Conditions
- NSCLC Stage IV
- EGFR T790M-negative
- Anlotinib
- JS001
Sponsors & Collaborators
-
Baodong Qin
lead OTHER
Eligibility
- Min Age
- 18 Months
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-01
- Primary Completion
- 2021-09-30
- Completion
- 2021-09-30
Countries
- China
Study Locations
More Related Trials
-
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
NCT03766490 ·Status: UNKNOWN ·Phase: NA
-
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
NCT05271916 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
NCT04770688 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
NCT04923906 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer
NCT05715398 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
NCT04871997 ·Status: COMPLETED
-
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
NCT04671303 ·Status: COMPLETED ·Phase: PHASE2
-
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
NCT04500717 ·Status: UNKNOWN ·Phase: PHASE3
-
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
NCT04028778 ·Status: UNKNOWN ·Phase: PHASE3
-
Liposomal Irinotecan and Apatinib in ES-SCLC
NCT06749691 ·Status: RECRUITING ·Phase: PHASE2
-
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
NCT04619537 ·Status: UNKNOWN ·Phase: PHASE2
-
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
NCT04619563 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
NCT04448379 ·Status: UNKNOWN ·Phase: PHASE1
-
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
NCT04500704 ·Status: UNKNOWN ·Phase: PHASE3
-
Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance
NCT04785729 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
NCT05685550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT05430386 ·Status: UNKNOWN ·Phase: PHASE1
-
Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC
NCT05218759 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT04870190 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
NCT04951648 ·Status: UNKNOWN ·Phase: PHASE3
-
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
NCT06102928 ·Status: RECRUITING ·Phase: NA
-
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
NCT06182761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
NCT05132777 ·Status: UNKNOWN ·Phase: PHASE2